Allan CJ, Halushka PV. Characterization of human peripheral blood monocyte thromboxane A 2 receptors. J Pharmacol Exp Ther 1994; 270: 446-52.

Anderson TJ, Meredith IT, Charboneau F, Yeung AC, Frei B, Selwyn AP, et al. Endothelium- dependant coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93: 1647-1650.

Auch-Schwelk W, Katusic ZS , Vanhoutte PM. Thromboxane A 2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 1990; 15: 699.

Babenko A, Vassort G. Enhancement of the ATP-sensitive K current by extracellular ATP in rat ventricular myocytes. Circ Res 1997; 80: 589-600.

Baan J, Van der Velde ET: sensitivity of left ventricular end-systolic pressure-volume relation to type of loading intervention in dogs. Circ Res 1988; 62: 1247-1258.

Baan J, Van der Velde ET, De Bruin HG, Smeenk G, Koops J, Van Dijk A, Temmerman D, Senden J, Buis B: Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 1984; 70: 812-823.

Barden A, Ritchie J, Walters B, Michael C, Rivera J, Mori T , et al. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertension 2001; 38: 803-8.

Batshake B, Nilsson C, Sundelin J. Structure and expression of the murine thromboxane A 2 receptor gene. Biochem Biophys Res Commun 1999; 256: 391-7.

Baylis C. Effects of administered thromboxanes on the intact, normal rat kidney. Ren Physiol 1987; 10: 110-21.

Beasley RC, Featherstone RL, Church MK, Rafferty P, Varley JG, Harris A , et al. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol 1989; 66: 1685-93.

Becker LC, Jeremy RW, Schaper J, SchaperW. Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog. Am J Physiol 1999 ; 277:H243.

Beitz A, Taube C, Beitz J, et al. Influence of drugs on the TXA2/PGI2 balance and on the atherogenic index in myocardial ischemia in dogs. Biomed Biochim Acta 1988; 47:S149–52.

Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A 2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-204.

Bergel D, Milnor WR: Pulmonary vascular impedance in the dog. Cir Res 1965; 16: 401-415.

Bertolino F, Valentin JP, Patoiseau JF, Rieu JP, Colpaert FC, John GW. Evidence for partial agonist properties of daltroban (BM 13,505) at TP receptors in the anaesthetized open-chest rat. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 462-6.

Bhat AM, Sacks H, Osborne JA, et al. Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats. Am Heart J 1989; 117:799–803.

Birks EJ, Yacoub MH. The role of nitric oxide and cytokines in heart failure. Corn Artery Dis 1997; 8: 389-402.

Blackman SC, Dawson G, Antonakis K, Le Breton GC. The identification and characterization of oligodendrocyte thromboxane A2 receptors. J Biol Chem 1998; 273: 475-83.

Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–1528.

Bonnefont-Rousselot D, Peynet J, Beaudeux JL, Therond P, Legrand A, Delattre J . Nutrition clinique et métabolisme 2002 ; 4 : 260-267.

Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP and Versteeg HH. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004; 36: 1187-1205.

Bouchard JF, Dumont E, Lamontagne D. Evidence that prostaglandins I 2, E 2, and D 2 may activate ATP sensitive potassium channels in the isolated rat heart. Cardiovasc Res 1994; 28: 901-5.

Boussairi EH, Sacquet J, Sassard J and Benzoni D . Thromboxane A 2- prostaglandin H 2 and renovascular hypertension in rats. Am J Physiol 1994; 267: R1190-R1197.

Bowling N, Dubé GP, Kurtz WL, Brune KA, Saussy DL Jr, Dorn GW 2nd, Mais DE.

Characterization of thromboxane A 2/prostaglandin H 2 binding sites in guinea pig cardiac membrane preparations. J Mol Cell Cardiol 1994; 26(7):915-23.

Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–1102.

Breyer RM, Bagdassarian CK, Myers SA and Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.

Brezinski ME, Yanagisawa A, Lefer AM. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia. J Cardiovasc Pharmacol 1987;9:65–71.

Brezinski ME, Yanagisawa A, Darius H, et al. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats. Am Heart J 1985; 110:1161–7.

Brinkmann A , et al. Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2- exchange and energy metabolism during hyperdynamic porcine endotoxemia. Shock 2000; 13: 307-13.

Bruggeman LA, Horigan EA, Horikoshi S, Ray PE and Klotman PE . Thromboxane stimulates synthesis of extracellular matrix proteins in vitro. Am J Physiol 1991. 261: F488-F494.

Burkhoff D, Sagawa K: Ventricular efficiency predicted by an analytical model. Am J Physiol Regul Integr Comp Physiol 1986; 250: R1021-1027.

Burkhoff D, Sugiura S, Yue DT, Sagawa K: Contractility-dependent curvilinearity of end- systolic pressure-volume relations. Am J Physiol Heart Circ Physiol 1987; 252: H1218-H1227.

Camacho M, Lopez-Belmonte J, Vila L: Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res 1998; 83: 353–365.

Campbell WB, Halushka PV. Lipid-derived autacoids: eicosanoïdes and platelet-activating factor. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9 th ed. New York: McGraw- Hill 1996: 601-16.

Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78: 415-23.

Carvalho MH, Fortes ZB, Nigro D, Oliveira MA and Scivoletto R. The role of thromboxane A 2 in the altered microvascular reactivity in two-kidney, one-clip hypertension. Endothelium 1997; 5: 167-178.

Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Gaetani P, et al. Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 1989; 49: 1505-8.

Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoïde production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001a; 167: 2831-8.

Caughey GE, Cleland LG, Gamble JR, James MJ. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A 2. J Biol Chem 2001b; 276: 37839- 45.

Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.

Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP , et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-4.

Chan PS and Cervoni P . Prostaglandins, prostacyclin, and thromboxane in cardiovascular diseases. Drug Dev Res 1986; 7: 341-359.

Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A 2. Science 2002; 296: 539-41.

Chiang N, Kan WM, Tai HH. Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A 2 receptor in insect cells. Arch Biochem Biophys 1996; 334: 9-17.

Cimetiere B, Dubuffet T, Landras C, Descombes JJ, Simonet S,Verbeuren TJ , et al. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors. Bioorg Med Chem Lett 1998a; 8: 1381-6.

Cimetiere B, Dubuffet T, Muller O, Descombes JJ, Simonet S, Laubie M , et al. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett 1998b; 8: 1375-80.

Cocker SJ, Parratt JR, Ledingham IM, Zeitlin IJ. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 1981;291:323.

Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P. Comparison of the actions of U-

46619, a prostaglandin H 2- analogue, with those of prostaglandin H 2 and thromboxane A 2 on some isolated smooth muscle preparations. Br J Pharmacol 1981; 73: 773-8.

Coleman RA, Kennedy I, Humphrey PPA, et al. Prostanoids and their receptors. In: Emmett JC, ed. Comprehensive Mechanical Chemistry Vol. 3 : Membranes and Receptors. Oxford, UK: Pergamon Press; 1990: 643-714.

Dallinger KJ, Jennings PE, Toop MJ, Gyde OH, Barnett AH. Platelet aggregation and coagulation factors in insulin dependent diabetics with and without microangiopathy. Diabet Med 1987; 4: 44-8.

D'Angelo DD, Terasawa T, Carlisle SJ, Dorn GW, 2nd, Lynch KR. Characterization of a rat kidney thromboxane A2 receptor: high affinity for the agonist ligand I-BOP. Prostaglandins 1996; 52: 303-16.

D'Angelo DD, Eubank JJ, Davis MG, Dorn GW, 2nd. Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling. J Biol Chem 1996; 271: 6233-40.

Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574-7.

Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 2001; 89: 650-60.

Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III-27-III-32. de Leval X, Benoit V, Delarge J, Julemont F, Masereel B, Pirotte B, et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 55-9.

Delpy E, Coste H, Gouville AC. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol 1996; 119: 471-8.

Denslow S. Relationship between PVA and myocardial oxygen consumption can be derived from thermodynamics. Am J Physiol Heart Circ Physiol 1996; 270: H730-H740.

Depin JC, Vigie A, Chavernac G, Rousselot C, Lardy C, Guerrier D. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A 2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Arzneimittelforschung 1994; 44: 1203-7.

Devillier P, Bessard G. Thromboxane A 2 and related prostaglandins in airways. Fundam Clin Pharmacol 1997; 11: 2-18.

Dogne JM, de Leval X, Delarge J, David JL, Masereel B. New trends in thromboxane and prostacyclin modulators. Curr Med Chem 2000a; 7: 609-28.

Dogne JM, de Leval X, Neven P, Rolin S, Wauters J, David JL , et al. Effects of a novel non- carboxylic thromboxane A 2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids 2000b; 62: 311-7.

Dogne JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J , et al. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev 2001a; 19: 87-96.

Dogne JM, Wouters J, Rolin S, Michaux C, Pochet L, Durant F , et al. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A 2 receptor antagonist and thromboxane synthase inhibitor. J Pharm Pharmacol 2001b; 53: 669-80.

Dogne JM, De Leval X, Benoit P, Delarge J, Masereel B. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med 2002; 1: 11-7.

Dogne JM, de Leval X, Kolh P, Sanna V, Rolin S, Michaux C , et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 49-54.

Dogne JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A , et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 2004a; 11: 1223-41.

Dogne JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, et al. Pharmacological characterization of N-tert-butyl-N'-[2-(4'- methylphenylamino)-5-nitrobenzenesulfonyl] urea

(BM-573), a novel thromboxane A 2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol Exp Ther 2004b; 309: 498-505.

Dorn GW, 2nd. Distinct platelet thromboxane A 2/prostaglandin H 2 receptor subtypes. A radioligand binding study of human platelets. J Clin Invest 1989; 84: 1883-91.

Dorn GW, 2nd, DeJesus A. Human platelet aggregation and shape change are coupled to separate thromboxane A 2-prostaglandin H 2 receptors. Am J Physiol 1991; 260: H327-34.

Dorn GW, 2nd, Davis MG, D'Angelo DD. Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors. Analysis of chimeric rat/human TP receptors. J Biol Chem 1997; 272: 12399-405.

Dorn GW, 2nd. Role of thromboxane A 2 in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 1997; 48: 42-62.

Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1992; 91: 29-37.

Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.

Elliott SJ, Lacey DJ, Chilian WM, Brzezinska AK. Peroxynitrite as a contractile agonist of cerebral artery smooth muscle cells. Am J Physiol 1998; 275: H1585-91.

Ellis EF, Oelz O, Roberts LJ, 2nd, Payne NA, Sweetman BJ, Nies AS , et al. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science 1976; 193: 1135-7.

Elzinga G, Westerhof N. Pressure and flow generated by the left ventricle against different impedances. Circ Res 1973; 32: 178-186.

Engler RL, Dahlgren MD, Morris DD, Petersen MA, Schmid-Schonbein GW. Role of leukocytes in response to acute myocardial ischaemia and reflow in dogs. Am J Physiol 1986; 251: H 1314- 1322.

Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder. Am J Physiol Heart Circ Physiol 2006; 291: H985-H1002.

Ferguson JJ, Miller MJ, Sahagian P, Aroesty JM, Mckay RG. Assessment of aortic pressure- volume relationships with an impedance catheter. Cathet Cardiovasc Diagn 1988; 15: 27-36.

Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 1990; 81: I69-78; discussion I79- 80.

Fiedler VB, Seuter F, Perzborn E, et al. Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease. Stroke 1990; 21: 149-51

Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, and Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981; 101:593–600.

Fitzgerald DJ, Roy L, Catella F, and Fitzgerald GA. Platelet activation in unstable coronary disease. New Engl J Med 1986; 315:983–9.

Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A 2 modulate the response to tissuetype plasminogen activator in vivo . Circ Res 1989; 65: 83-94.

FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D. Cyclooxygenase products and atherothrombosis. Ann Med 2000; 32 Suppl 1: 21-6.

FitzGerald GA: COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879–890

Flavahan NA. Balancing prostanoid activity in the human vascular system. TRENDS in pharmacological sciences 2006; 28:106-110.

Forman MB, Puett DW, Virmani R. Endothelial and myocardial injury during ischaemia and reperfusion: pathogenesis and therapeutic implications. J Am Coll Cardiol 1989; 13: 450-459.

Forstermann U, Pollock JS, Nakane M. Nitric oxide synthase in the cardiovascular system. Trends Cardiovasc Med 1993; 3: 104.

Fourie PR, Coetzee AR, Bolliger CT. Pulmonary artery compliance: its role in right ventricular- arterial coupling. Cardiovasc Res 1992: 26(9): 839-44.

Francois H, Athirakul K, Mao L, et al. Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 2004; 43: 364-9.

Frank O. Zur Dynamic des Herzmuskels. Z Biol 1895; 32: 370-447.

Freeman GL, Little WC, O’Rourke RA. The effect of vasoactive agents on the left ventricular end-systolic pressure-volume relation in closed-chest dogs. Circulation 1986; 74: 1107-1113.

Fukumoto S, Shiraishi M, Terashita Z, Ashida Y, Inada Y. Synthesis and thromboxane

A2/prostaglandin H 2 receptor antagonistic activity of phenol derivatives. J Med Chem 1992; 35: 2202-9.

Fukunaga M, Makita N, Roberts LJ, 2nd, Morrow JD, Takahashi K, Badr KF. Evidence for the existence of F 2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 1993; 264: C1619-24.

Fukunaga M, Yura T, Grygorczyk R, Badr KF. Evidence for the distinct nature of F 2-isoprostane receptors from those of thromboxane A 2. Am J Physiol 1997; 272: F477-83.

Funk CD, Furci L, Moran N, Fitzgerald GA. Point mutation in the seventh hydrophobic domain of the human thromboxane A 2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol 1993; 44: 934-9.

Furchgott RF, Zawadzki JV. The obligatory role of endothelium cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.

Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989; 3: 2007.

Gaasch WH, Battle WE, Okoler AA, Banas JSJ, Levine HJ. Left ventricular stress and compliance in man; with special reference to normalized ventricular function curves. Circulation 1972; 45: 746-762.

Galipeau D, Arikawa, Sekirov I and McNeill JH . Chronic Thromboxane synthase inhibition prevents ructose-induced hypertension. Hypertension 2001; 38: 872-876.

Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704-18.

Ge ZD, Auchampach JA, Piper GM, Gross GJ. Comparison of cardioprotective efficacy of two thromboxane A 2 receptor antagonists. J Cardiovasc Pharmacol 2003; 41: 481-488

Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 1998; 17: 7-23.

Ghuysen A, Lambermont B, Dogne JM, Kolh P, Tchana-Sato V, Morimont P , et al. Effect of BM-573, a dual thromboxane synthase inhibitor and TP receptor antagonist, in a porcine model of acute pulmonary embolism. J Pharmacol Exp Ther 2004; 310: 964-72.

Ghuysen A, Dogné JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc Drug Rev 2005; 23(1):1-14.

Gibbs CL. Cardiac energetics. Physiol Rev 1978; 58: 175-254.

GISSI Investigators. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet 1986; 1:397.

Glower D, Spratt J, Snow TR, Kabas JS, Davis JW, Olsen C, Tyson G, Sabiston DC, Rankin J. Linearity of the Frank-Starling relationship in the intact heart: The concept of preload recruitable stroke work. Circulation 1985; 71: 994-1009.

Golino P, Ambrosio G, Villari B, et al. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. J Am Coll Cardiol 1993; 21:493.

Gonzalez ER. Antiplatelet therapy in atherosclerotic cardiovascular disease. Clin Ther 1998; 20 Suppl B: B18-41.

Grant BJ and Paradowski LJ. Characterization of pulmonary arterial input impedance with lumped parameter models. Am J Physiol 1987; 252: H585-93.

Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1984; 1: 991- 4.

Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-45.

Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I. Basic mechanisms and in vivo monitoring of ROS. Circulation 2003a; 108: 1912-1916.

Griending KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II. Animal and human studies. Circulation 2003b; 108: 2034-2040.

Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328:673.

Grosser T, Zucker TP, Weber AA, Schulte K, Sachinidis A, Vetter H, et al. Thromboxane A 2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen. Eur J Pharmacol 1997; 319: 327-32.

Grosser T, et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15.

Grossman W, Braunwald E, Mann T, McLaurin L, Green L. Contractile state of left ventricle in man as evaluated from end-systolic pressure-volume relations. Circulation 1977; 56: 845-852.

Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1999; 274: 2645-51.

Haga Y, Hatori N, Nordlander M, Nordlander R, Sjoquist PO, Ryden L. Coronary venous retroinfusion of felodipine reducing infarct size without affecting regional myocardial blood flow. Eur Heart J 1993; 14:1386.

Halmos T, Turek JW, Le Breton GC, Antonakis K. Synthesis and biological characterization of sqbazide, a novel biotinylated photoaffinity probe for the study of the human platelet thromboxane A 2 receptor. Bioorg Med Chem Lett 1999; 9: 2963-8.

Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62: 1676-81.

Halushka PV, Allan CJ and Davis-Bruno KL . Thromboxane A 2 receptors. J Lipid Mediators Cell Signalling 1995; 12: 361-378.

Halushka PV. Thromboxane A 2 receptors: where have you gone? Prostaglandins Other Lipid Mediat 2000; 60: 175-89.

Hamberg M, Svensson J, Wakabayashi T, Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A 1974; 71: 345-9.

Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975; 72: 2994-8.

Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W, Weber PC. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987; 10: 998- 1006.

Hatori N, HagaY, Sjoquist PO, Nordlander M, Ryden L. Coronary venous retroinfusion of felodipine reduces myocardial necrosis after coronary occlusion and reperfusion. J Cardiovasc Pharmacol 1993;22:160.

Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem 1985; 260: 15059-67.

Hearse DJ, Humphrey SM, Nayler WG, Slade A, Border D. Ultrastructural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol 1975;7:315.

Hendra T, Betteridge DJ. Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1989; 35: 197-212.

Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J M 2002; 346: 1954-1962.

Higo K, Karasawa A, and Kubo K . Early thrombolysis by recombinant tissue plasminogen activator is beneficial to the ischemic myocardium. J Pharmacobiodyn 1992;15:33–37.

Higo K, Sano J, Karasawa A, Kubo K. The novel thromboxane A 2 receptor antagonist KW-3635 reduces infarct size in a canine model of coronary occlusion and reperfusion. Arch Int Pharmacodyn Ther 1993;323:32.

Hinz B, Brune K: Cyclooxygenase-2 – 10 years later. J Pharmacol Exp Ther 2002; 300: 367-375

Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S , et al. Cloning and expression of cDNA for a human thromboxane A 2 receptor. Nature 1991; 349: 617-20.

Hirsh PD, Hillis LD, Campbell WB, Firth BG, and Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. New Engl J Med 1981; 304:685–691.

Hirsh PD, Firth BG, Campbell WB, Dehmer GJ, Willerson JT, and Hillis LD . Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. Am J Cardiol 1983; 51:727–733.

Hock CE, Brezinsky ME, and Lefer AM. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29, 548, in acute myocardial ischemia. Eur J Pharmacol 1986; 122:213–219.

Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992; 18: 392-415.

Horie T, Sekiguchi M, and Hirosawa K. Coronary thrombosis in pathogenesis of acute myocardial infarction. Histopathological study of coronary arteries in 108 necropsied cases using serial section. Br Heart J 1978; 40:153–161.

Huttner IG, Gabbiani G. Vascular endothelium in hypertension. In Hypertension, edited by Genest J, Kuchel O, Hamet P, and Cantin M. New York: McGraw-Hill, 1983, p. 473-488.

Hwang TL, Yeh YA, Chern JW, Teng CM. Pharmacological characterization of EK112, a new combined angiotensin II and thromboxane A 2 receptor antagonist. Gen Pharmacol 2000; 34: 25-31.

Ignarro LJ. Heme-dependent activation of soluble guanylate cyclase bynitric oxide: regulation of enzyme activity by porphins and metalloporphyrins. Semin Hematol 1989; 26: 63.

Imamoto T, Terashita Z, Tanabe M, Nishikawa K, Hirata M. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs. J Cardiovasc Pharmacol 1986;8: 832.

Ishii H, Umeda F, Nawata H. Platelet function in diabetes mellitus. Diabetes Metab Rev 1992; 8: 53-66.

I-Shing Y, Shu-Rung L, Chin-Chin H, et al. TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 2004; 104: 135-42.

Jankov RP, Belcastro R, Ovcina E, Lee J, Massaeli H, Lye SJ , et al. Thromboxane A 2 receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase independent mechanism. Am J Respir Crit Care Med 2002; 166: 208-14.

Jennings RB, Ganote CE. Mitochondrial structure and function in acute myocardial ischemic injury. Circ Res 1976;38(Suppl. 1):I80.

Kanao M, Watanabe Y, Kimura Y, Saegusa J, Yamamoto K, Kanno H , et al. Thromboxane A 2 synthetase inhibitors. 2.Syntheses and activities of tetrahydronaphthalene and indan derivatives. J Med Chem 1989; 32: 1326-34.

Karasawa A, Shirakura S, Higo K, Kubo K. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5, 6- dimethyl-1-benzimidazolyl)-ethylidene]-6, 11 dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations. Arzneimittelforschung 1991; 41: 1237-41.

Kass DA, Yamazaki T, Burkhoff D, Maughan WL, Sagawa K. Determination of left ventricular end-systolic pressure –volume relationship by the conductance (volume) catheter technique. Circulation 1986; 73: 586-595.

Kass DA, Midei M, Graves W, Maughan WL. Use of a conductance catheter and transient inferior vena caval occlusion for rapid determination of pressure-volume relationships in man. Cathet Cardiovasc Diagn 1988; 15: 192-202.

Kass DA, Marino P, Maughan W, Sagawa K. Determinants of end-systolic pressure–volume relations during acute regional ischemia in situ. Circulation 1989; 80:1783.

Kato T, Iwama Y, Okumura K, Hashimoto H, Ito K, Satake T. Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990; 15: 475.

Kause K, Stekiel WJ, Rubanyi G, Harder DR. Mechanism of action of EDRFon pressurized arteries: effect on K+ conductance. Circ Res 1989; 65: 199.

Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 2002; 283: R29-45.

Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM ,et al. Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the protooncogenic factor ets-1. Oncogene 2003; 22: 7716-27.

Klausner JM, Paterson IS, Valeri CR, Shepro D, Hechtman HB. Limb ischemia-induced increase in permeability is mediated by leukocytes and leukotrienes. Ann. Surg 1988; 208: 755.

Koba S, Pakala R, Watanabe T, Katagiri T, Benedict CR. Synergistic interaction between thromboxane A 2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 329-35.

KoenigW. Inflammation and coronary heart disease: an overview. Cardiol Rev 2001;9:31–35.

Kolh P, D’orio V, Lambermont B, Gerard P, Gommes C, Limet R. Increased aortic compliance decreases the energetic cost of left ventricular ejection. J Cardiac Failure 2000a; 6(suppl 2): 10.

Kolh P, D’orio V, Lambermont B, Gerard P, Gommes C, Limet R. Increased aortic compliance maintains left ventricular performance at lower energetic cost. Eur J Cardiothorac Surg 2000b; 17: 272-278.

Kolh P, Ghuysen A, Tchana-Sato V, D’orio V, Gerard P, Morimont P, Limet R, Lambermont B. Effects of increased afterload on left ventricular performance and mechanical efficiency are not baroreflex-mediated. Eur J Cardiothorac Surg 2003 ; 24: 912-9.

Krötz F, Schiele T M, Klauss Volker, Sohn Hae-Young. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005; 42: 312-324.

Kurokawa T, Matsumoto T, Ashida Y, Sasada R, Iwasa S. Antagonism of the human thromboxane A2 receptor by an antiasthmatic agent AA-2414. Biol Pharm Bull 1994; 17: 383-5.

Kurzel F, Hagel C, Zapf S, Meissner H, Westphal M, Giese A. Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells. Acta Neurochir (Wien) 2002; 144: 71-87.

Kuzuya T, Hoshida S, Nishida M, Kim Y, Kamada T, Tada M. Increased production of arachidonate metabolites in an occlusion–reperfusion model of canine myocardial infarction. Cardiovasc Res 1987; 21:551-8.

Lambermont B, D’orio V, Kolh P, et al. Time domain method to identify simultaneously parameters of the windkessel model applied to the pulmonary circulation. Arch Physiol Biochem 1998; 106: 245-252.

Lambermont B, Kolh P, Detry O, et al. Analysis of endotoxin effects on the intact pulmonary circulation. Cardiovasc Res 1999; 41: 275-81.

Lambermont B, Kolh P, Dogne JM, et al. Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A 2 inhibitor. Arch Physiol Biochem 2003a; 111: 217-23.

Lambermont B, Ghuysen A, Dogne JM, et al. Effects of BM-573, a novel thromboxane A 2 inhibitor, on pulmonary hemodynamics in endotoxic shock. Arch Physiol Biochem 2003b; 111: 224-31.

Lambermont B, Kolh P, Ghuysen A, Segers P, Dogne JM, Tchana-Sato V , et al. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. Shock 2004; 21: 45-51.

Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: II27-33.

Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4- chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Arzneimittelforschung 1994; 44: 1196-202.

Laskey W, Parker H, Ferrari V, Kussmaul W, Noodergraaf A. Estimation of total systemic arterial compliance in humans. J Appl Physiol 1990; 69: 112-119.

Lauer B, Niederau C, Ku¨ hl U, Schannwell M, Pauschinger M, Strauer BE, and Schultheiss HP. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30:1354–1359.

Lee JD, Tajimi T, Widman TF, Ross J. Application of end-systolic pressure –volume and pressure-wall thickness relations in conscious dogs. J Am Coll Cardiol 1987; 9: 136-146.

Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001; 21: 1291-4.

Lehr HA, Guhlmann A, Nolte D, Keppler D, Messmer K. Leukotrienes as mediators in ischemia- reperfusion injury in a microcirculation model in the hamster. J. Clin. Invest 1991; 87: 2036.

Lefer AM, Darius H. A pharmacological approach to thromboxane receptor antagonism. Fed Proc 1987; 46: 144-8.

Lerner RW, Lopaschuk GD, Catena RC, Olley PM. [3H]iloprost and prostaglandin E2 compete for the same receptor site on cardiac sarcolemmal membranes. Biochim Biophys Acta 1992 ; 1105(2):189-92.

Li JK, Cui T, Drzewiecki G. A non-linear model of the arterial system incorporating a pressure- dependent compliance. IEEE Trans Biomed Eng 1990; 37:673-678.

Lie JT, Pairolero PC, Holley KE, and Titus JL .Macroscopic enzyme-mapping verification of large, homogeneous, experimental myocardial infarcts of predictable size and location in dogs. J Thorac Cardiovasc Surg 1975; 69:599–605.

Lin L and Nasjletti A. Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction. Hypertension 1991; 18: 158-64.

Lüscher TF, Vanhoutte PM. The endothelium: Modulator of cardiovascular function. CRC press, Boca Raton . 1990.

Luscher TF, Boulanger CM, Dohi Y, Yang ZH. Endothelium derived contracting factors. Hypertension 1992; 19: 117-30.

Lüscher TF. Platelet-vessel wall interaction: role of nitric oxide, prostaglandins and endothelins. Baillieres Clin Haematol 1993; 6(3):609-27.

Lüscher TF, Noll G. The pathogensis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995; 118: S81–S90.

Lüscher TF, Oemar BS, Boulanger CM, Hahn AWA. Molecular and cellular biology of endothelin and its receptors. In: Lindpainter K, Ganten D, editors. Molecular reviews. London: Chapman & Hall; 1996; 96-104.

Mais DE, Saussy DL, Jr., Chaikhouni A, Kochel PJ, Knapp DR, Hamanaka N , et al.

Pharmacologic characterization of human and canine thromboxane A 2/prostaglandin H 2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther 1985; 233: 418-24.

Mais DE, DeHoll D, Sightler H, Halushka PV. Different pharmacologic activities for 13- azapinane thromboxane A 2 analogs in platelets and blood vessels. Eur J Pharmacol 1988; 148: 309-15.

Mallat Z, Nakamura T, Ohan J, Leseche G, Tedgui A, Maclouf J , et al. The relationship of hydroxyeicosatetraenoic acids and F 2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 1999; 103: 421-7.

Mason RP, Walter MF, Day CA, Jacob RF. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX 2 selective agents and NSAids. Subcell Biochem 2007; 42: 175-90.

Matejovic M, Radermacher P, Zulke C, Vlatten A, Altherr J, Mehta JL, Lawson D, Mehta P,

Saldeen T. Increased prostacycline and thromboxane A 2 biosynthesis in atherosclerosis. Proc Natl Acad Sci U S A 1988; 85: 4511-5.

Maughan WL, Shoukas A, Sagawa K, Weisfeldt M. Instantaneous pressure-volume relationship of the canine right ventricle. Circ Res 1979; 44: 309-315.

Maughan WL, Sunagawa K, Burkhoff D, Sagawa K. Effects of arterial impedance changes on the end-systolic pressure volume relation. Circ Res 1984; 54: 595-602.

Mazolewski PJ, Roth AC, Suchy H, Stephenson L, Zamboni WA. Role of the thromboxane A 2 receptor in the vasoactive response to ischemia-reperfusion injury. Plast. Reconstr. Surg 1999; 104(5): 1393-6.

McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacycline by cyclooxygenase (COX)-2 – the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96: 272–7.

Mckay RG, Aroesty JM, Heller GV, Royal HD, Grossman W. Assessment of the end-systolic pressure-volume relationship in human beings with the use of a tima varying élastance model. Circulation 1986; 74: 97-104.

McLemore TL, Hubbard WC, Litterst CL, Liu MC, Miller S, McMahon NA , et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 1988; 48: 3140-7.

Mehmel H, Stockins K, Ruffman K, Olshansen G, Schuler B, Kubler W. The linearity of the end- systolic pressure-volume relation in man and its sensitivity for assessment of left ventricular function. Circulation 1981; 63: 1216-1222.

Mehta P, Lawson D, Ward MB, Lee-Ambrose L, Kimura A.Effects of thromboxane A 2 inhibition on osteogenic sarcoma cell induced platelet aggregation. Cancer Res 1986; 46: 5061-3.

Merimee TJ. Diabetic retinopathy. A synthesis of perspectives. N Engl J Med 1990; 322: 978-83.

Michaux C, Rolin S, Dogne JM, Durant F, Masereel B, Delarge J , et al. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition. Bioorg Med Chem Lett 2001; 11: 1019-22.

Miki I, Kase H, Ishii A. Differences in activities of thromboxane A2 receptor antagonists in smooth muscle cells. Eur J Pharmacol 1992; 227: 199-204.

Milnor WR. Arterial impedance as ventricular afterload. Circ Res 1975; 36: 565-570.

Milnor WR. Hemodynamics. Baltimore: Williams &Wilkins, 1982, pp 1-390.

Minoguchi K, Adachi M. [Thromboxane A 2 synthase inhibitor and receptor antagonist]. Nippon Rinsho 2001; 59: 1986-91.

Mirsky I: Elastic properties of the myocardium: a quantitative approach with physiological and clinical applications. In: Bern RM, Sperelakis N & Geiger S, eds. Handbook of physiology, Sec.2. The Cardiovascular System, Vol. 1.: Bethesda American Physiologic Society, 1979, pp 497-531.

Mistry M, Nasjletti A . Prostanoids as mediators of prohypertensive and antihypertensive mechanisms. Am J Med Sci 1988; 295: 263-267.

Miura H, Gutterman DD. Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca-activated K channels. Circ Res 1998; 83: 501-7.

Miyata A, Yokoyama C, Ihara H, Bandoh S, Takeda O, Takahashi E, et al. Characterization of the human gene (TBXAS1) encoding thromboxane synthase. Eur J Biochem 1994; 224: 273-9.

Miyazaki S, Fujiwara H, Onodera T, et al. Quantitative analysis of contraction band and coagulation necrosis after ischemia and reperfusion in the porcine heart. Circulation 1987;75:1074.

Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A 2, and prostacyclin. Pharmacol Rev 1978; 30: 293-331.

Moncada S, Higgs E . Arachidonate metabolism in blood cells and the vessel wall. Clinics in Haematology 1986; 15: 273-287.

Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.

Moreno A, De La Cruz JP, Garcia Campos J, Sanchez De La Cuesta F. Prostacyclin- thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. Can J Ophthalmol 1995; 30: 117-23.

Morinelli TA, Niewiarowski S, Daniel JL, Smith JB. Receptormediated effects of a PGH 2 analogue (U 46619) on human platelets. Am J Physiol 1987; 253: H1035-43.

Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ, 2nd. Formation of unique biologically active prostaglandins in vivo by a non-cyclooxygenase free radical catalyzed mechanism. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 125-8.

Morrow JD, Minton TA, Roberts LJ, 2nd. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 1992; 44: 155-63.

Mullane KM, Read N, Salmon JA, Moncada S. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther 1984; 228: 510-22.

Mullane KM, Fornabaio D. Thromboxane synthetase inhibitors reduce infarct size by a platelet- dependent, aspirin-sensitive mechanism. Circ Res 1988;62:668.

Nagao T, Vanhoutte PM. Hyperpolarization as a mechanism for endothelium-dependent relaxation in porcine coronary arteries. J Physiol 1992; 445: 355.

Namba T, Sugimoto Y, Hirata M, Hayashi Y, Honda A, Watabe A , et al. Mouse thromboxane A 2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun 1992; 184: 1197-203.

Nanji AA. Thromboxane synthase and organ preference for metastases. N Engl J Med 1993; 329: 138-9.

Narumiya S, Hirata N, Namba T, Hayashi Y, Ushikubi F, Sugimoto Y, et al. Structure and function of prostanoid receptors. J Lipid Mediat 1993; 6: 155-61.

Nasjletti A , Baer PG . Prostanoids in clinical and experimental hypertension. In: Eicosanoids in the Cardiovascular and Renal Systems , PV Halushka and DE Mais, eds. Lancaster, PA: MTP Press, 1988, pp. 159-175.

Nasjletti A, Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin- dependent hypertension. Hypertension 1998; 31: 194-200.

Needleman P, Minkes M, Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science 1976a; 193: 163-5.

Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A 2 from prostaglandin endoperoxides. Nature 1976b; 261: 558-60.

Nichols WW, Mehta J, Wargovich TJ, Franzini D, Lawson D. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist. Angiology 1989; 40:209-21.

Nichols WW, O’rourke MF. Aging, high blood pressure and disease in humans. McDonald’s Blood Flow in Arteries: Theoretic, Experimental, and Clinical Principles. Baltimore, Md: Edward Arnold Publishers, Ltd, 1990, pp 398-420.

Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K , et al. Thromboxane A 2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 2000; 267: 245-51.

Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F , et al. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary- mucinous tumors of the pancreas. Cancer 2002; 94: 1565-73.

Norel X et al.. Prostanoid receptors in the human vascular wall. Scientific World Journal 2007; 7: 1359-74.

Nusing RM, Hirata M, Kakizuka A, Eki T, Ozawa K, Narumiya S. Characterization and chromosomal mapping of the human thromboxane A 2 receptor gene. J Biol Chem 1993; 268: 25253-9.

O’rourke MF. Vascular impedance in studies of arterial and cardiac function. Physiol Rev 1982, 62: 570-623.

Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ, 2nd. Clinical implications of prostaglandin and thromboxane A 2 formation (2). N Engl J Med 1988a; 319: 761- 7.

Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ, 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 1988b; 319: 689-98.

Ogletree ML, Brigham KL. Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep. Prostaglandins Leukot Med 1982; 8: 489-502.

Ogletree ML. Overview of physiological and pathological effects of thromboxane A 2. Fed. Proc 1987; 46: 133-138.

Olsen CO, Tyson GS, Maier GW, Spratt JA, Davis JW, Rankin JS. Dynamic ventricular interaction in the conscious dog. Circ Res 1983, 52: 85-104.

Opie LH. Reperfusion injury and its pharmacologic modification. Circulation 1989; 80:1049- 1062.

Pace-Asciak CR, Reynaud D, Demin P, Aslam R, Sun A. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. J Pharmacol Exp Ther 2002; 301: 618-24.

Pakala R, Benedict CR. Effect of serotonin and thromboxane A 2 on endothelial cell proliferation: effect of specific receptor antagonists. J Lab Clin Med 1998; 131: 527-37.

Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L- arginine. Nature 1988; 333: 664-6.

Panes J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999; 126: 537-550.

Parent JL, Labrecque P, Orsini MJ, Benovic JL. Internalization of the TXA 2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 1999; 274: 8941-8.

Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990; 81: I12-5; discussion I22-3.

Patscheke H, Stegmeier K, Muller-Beckmann B, Sponer G, Staiger C, Neugebauer G. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Biomed Biochim Acta 1984a; 43: S312-8.

Patscheke H & Stegmeier K. Investigation on a selective nonprostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb Res 1984b; 33: 277-88.

Patscheke H, Hornberger W, Zehender H. Pathophysiological role of thromboxane A 2 and pharmacological approaches to its inhibition. Z Kardiol 1990; 79 Suppl 3: 151-4.

Pawlowski NA, Kaplan G, Hamill AL, Cohn ZA, Scott WA. Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures. J Exp Med 1983; 158: 393-412.

Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci U S A 1980; 77: 4336-9.

Pearson TA, Kramer EC, Solez K, and Heptinstall RH (1977) The human atherosclerotic plaque. Am J Pathol 1977; 86:657–664.

Pepine CJ, Nichols WW, Curry R, Conti CR. Aortic input impedance during nitroprusside infusion . A reconsideration of afterload reduction and beneficial action. J Clin Invest 1979, 64: 643-654.

Pfister SL, Schmitz JM, Willerson JT, Campbell WB. Characterization of arachidonic acid metabolism in Watanabe heritable hyperlipidemic (WHHL) and New Zealand white (NZW) rabbit aortas. Prostaglandins 1988; 36: 515-32.

Pinto S, Gori L, Gallo O, Boccuzzi S, Paniccia R, Abbate R. Increased thromboxane A 2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 527-30.

Plutzky J. The vascular biology of atherosclerosis. Am J Med 2003; 115 (Suppl 8A): 55S-61S.

Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y , et al. Gene transfer of thromboxane A 2 synthase and prostaglandin I 2 synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002; 62: 63-6.

Pratico D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 1996; 271:14916-24.

Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA.Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 1998; 4: 1189- 92.

Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823-6.

Pries AR , Kuebler WM. Normal endothelium. Handb Exp Pharmacol 2006 ;( 176 Pt 1):1-40.

Qiao N, Reynaud D, Demin P, Halushka PV, Pace-Asciak CR. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cells. J Pharmacol Exp Ther 2003; 307: 1142-7.

Rankin JS, McHale PA, Arentzen CE, Ling D, Greenfield JC Jr, Anderson RW. The three- dimensional dynamic geometry of the left ventricle in the conscious dog. Circ Res 1976, 39: 304- 313.

Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A 2 receptor. J Biol Chem 1994; 269: 19256-61.

Redl G, Abdi S, Traber LD, Nichols RJ, Flynn JT, Herndon DN , et al. Inhibition of thromboxane synthesis reduces endotoxin-induced right ventricular failure in sheep. Crit Care Med 1991; 19: 1294-302.

Reeves WC, Demers LM, Wood MA, Skarlatos S, Copenhaver G, Whitesell L , et al. The release of thromboxane A 2 and prostacycline following experimental acute pulmonary embolism. Prostaglandins Leukot Med 1983; 11: 1-10.

Remuzzi G, FitzGerald GA and patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992; 41:1483-93.

Riess H, Hiller E, Reinhardt B, Brauning C. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. Thromb Res 1984; 35: 371-8.

Roald HE, Barstad RM, Engen A, Kierulf P, Skjorten F, Sakariassen KS. HN-11500--a novel thromboxane A 2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost 1994; 71: 103-9.

Roberts LJ, 2nd, Sweetman BJ, Oates JA. Metabolism of thromboxane B 2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981; 256: 8384-93.

Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A 2 receptor dependent signaling pathways. Faseb J 2001; 15: 1517-28.

Rolin S, Dogne JM, Michaux C, et al. Activity of a novel dual thromboxane A 2 receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 67-72.

Rolin S, Petein M, Tchana-Sato V, Dogne JM, Benoit P, Lambermont B , et al. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther 2003; 306: 59-65.

Rosentreter U, Boshagen H, Seuter F, Perzborn E, Fiedler VB. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1, 2, 3, 4- tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer. Arzneimittelforschung 1989; 39: 1519-21.

Ross R. Atherosclerosis –an inflammatory disease. N Engl J Med 1999; 340: 115-126.

Ruan KH, Wang LH, Wu KK, Kulmacz RJ. Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum. J Biol Chem 1993; 268: 19483-90.

Ruan KH, So SP, Wu J, Li D, Huang A, Kung J. Solution structure of the second extracellular loop of human thromboxane A 2 receptor. Biochemistry 2001; 40: 275-80.

Sachinidis A, Flesch M, Ko Y, et al. Thromboxane A 2 and vascular smooth muscle cell proliferation. Hypertension 1995; 26: 771-80.

Sagawa K, Maughan L, Suga H, Sunagawa K. Cardiac contraction and the Pressure- Volume Relationship. New York: Oxford University Press, 1988.

Sakuma I, Stuehr DJ, Gross SS, Nathan C, Levi R. Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85: 8664.

Saldeen P, Nilsson IM, Saldeen T. Increased synthesis of thromboxane B 2 and 6-keto-PGF1 alpha in hand veins from patients with deep venous thrombosis. Thromb Res 1983; 32: 461-7.

Saldeen TG, Saldeen P, Nichols WW, Lawson DL, Nicolini FA, Mehta JL. Increased production of thromboxane A 2 by coronary arteries after thrombolysis. Am Heart J 1993; 125: 277-84.

Sarnoff SJ, Braunwald E, Welch GH. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Phsiol 1958, 192: 148-156.

Sarnoff SJ, Berglund E. Starling’s law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation 1954, 9: 706-718.

Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.

Schmidt HH, Nau H, Wittfoht W, et al. Arginine is a physiological precursor of endothelium- derived nitric oxide. Eur J Pharmacol 1988; 154: 213.

Schror K, Thiemermann C. Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177). Br J Pharmacol 1986; 87:631.

Schubert R, Serebryakov VN, Mewes H, et al. Iloprost dilates rat small arteries: role of K ATP and

KCa channel activation by cAMP-dependent protein kinase. Am J Physiol 1997; 272: H1147- H1156.

Shimizu S, Ishii M, Yamamoto T, Kawanishi T, Momose K, et al. Bradykinin induces generation of reactive oxygen species in bovine aortic endothelial cells. Res Commun Chem Pathol pharmacol 1994; 84: 301-14.

Shimokawa H, Yasutake H, Fujii K, et al. Hyperpolarizing mechanism becomes more important as the vessel diameter becomes smaller in endothelium-dependent relaxations. Endothelium 1995; 2: S21.

Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999; 31: 23-37.

Shimokawa H, Vanhoutte PM. Endothelium and vascular injury in hypertension and atherosclerosis. In: Handbook of hypertension, Zanchetti A, Mancia G, eds. Elsevier, New York, in press.

Shinozaki K, Sato H, Iwakuma T, Sato R, Kurimoto T, Yoshida K. Synthesis and thromboxane

A2 antagonistic activity activity of indane derivatives. Bioorg Med Chem Lett 1999; 9: 401-6.

Signorelli SS, Neri S, Di Pino L, Costa MP, Pennisi G, Digrandi D, et al. Oxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosis. In: ClinExp M. 2001; 1: 9-12.

Singh J, Seth SD, Manchanda SC, et al. Protective actions of a thromboxane receptor antagonist, SQ 29548 on the ischemic myocardium: morphologic and hemodynamic effects. Prostaglandins Leukot Essent Fatty Acids 1997; 56:105–10.

Smith EF III, Lefer AM, Smith JB. Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Can J Physiol Pharmacol 1980; 58:294–300.

Smith EF III, Earl CQ, Egan JW. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion. Prostaglandins Leukot Essent Fatty Acids 1989; 38:15–23.

Smith WL . Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Ann Rev Physiol 1986; 48: 251-262.

Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res, 2000; 48: 23-33.

Klotz TA, Cohn LS, Zipser RD. Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease. Chest 1984; 85: 329-35.

Sodums MT, Badke FR, Starling MR, Little WC, O’rourke RA. Evaluation of left ventricular contractile performance utilizing end-systolic pressure-volume relationship in conscious dogs. Circ Res 1984, 54: 731-739.

Soyka R, Guth BD, Weisenberger HM, Luger P, Muller TH. Guanidine derivatives as combined thromboxane A 2 receptor antagonists and synthase inhibitors. J Med Chem 1999; 42: 1235-49.

Spotnitz HM, Sonnenblick EH, Spiro D. Relation of ultrastructure to function in the intact heart: sarcomere structure relative to pressure volume curves of intact left ventricles of dog and cat. Circ Res 1966, 18: 49-66.

Steendijk P, Van der Velde ET, Baan J. Left ventricular stroke volume by single and dual excitation of conductance catheter in dogs. Am J Physiol Heart Circ Physiol 1993, 264: H2198- H2207.

Stegmeier K, Pill J, Muller-Beckmann B, Schmidt FH, Witte EC, Wolff HP , et al. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb Res 1984; 35: 379-95.

Stergiopulos N, Meister JJ, Westerhof N. Evaluation of methods for estimation of total arterial compliance. Am J Physiology Heart Circ Physiol 1995, 268: H1540-H1548.

Su JB, Crozatier B. Preload-induced curvilinearity of left ventricular end-systolic pressure- volume relations. Effects on derived indexes in closed chest dogs. Circulation 1989, 79: 431-440.

Suga H. Time course of left ventricular pressure-volume relationship under various end-diastolic volumes. Jpn Heart J 1969, 10: 509-515.

Suga H. Time course of left ventricular pressure-volume relationship under various extents of aortic occlusion. Jpn Heart J 1970, 11: 373-378.

Suga H. Left ventricular time-varying pressure/volume ratio in systole as an index of myocardial inotropism. Jpn Heart J 1971, 12: 153-160.

Suga H. External mechanical work from relaxing ventricle. Am J Physiol Heart Circ Physiol 1979a, 236: H494-H497.

Suga H. Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am J Physiol Heart Circ Physiol 1979b, 236: H498-H505.

Suga H. Relaxing ventricle performs external mechanical work greater than quickly released elastic energy. Eur Heart J 1980, 1: 131-137.

Suga H, Sagawa K. Accurate measurement of absolute intraventricular volume. Rep Inst Med Dent Eng 1973, 7: 71-74.

Suga H, Sagawa K. Instantaneous pressure-volume relationships and their ratio in the excised , supported canine left ventricle. Circ Res 1974, 35: 117-126.

Suga H, Yamakoshi K. Effects of stroke volume and velocity of ejection on end-systolic pressure of canine left ventricle: End-systolic volume clamping. Circ Res 1977, 40: 454-450.

Suga H, Sagawa K, Shoukas A. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ res 1973, 32: 314-322.

Suga H, Sagawa K, Shoukas A. Carotid sinus baroreflex effects on instantaneous pressure- volume ratio of the canine left ventricle. J Physiol Soc Japan 1974, 36: 106-107.

Suga H, Hayashi Y, Shirahata M. Ventricular systolic pressure-volume area as predictor of cardiac oxygen consumption. Am J Physiol Heart Circ Physiol 1981a, 240: H39-H44.

Suga H, Hayashi Y, Shirahata M, Sueriho S, Hisano R. Regression of cardiac oxygen consumption on ventricular pressure-volume area in dog. Am J Physiol Heart Circ Physiol 1981b, 240: H320-H325.

Suga H, Hayashi Y, Suehiro S, Hisano R, Shirahata M, Ninomiya I. Equal oxygen consumption rates of isovolumic and ejecting contractions with equal systolic pressure-volume areas in canine left ventricle. Circ Res 1981c, 49: 1082-1091.

Suga H, Hisano R, Goto Y, Yamada O, Igarashi Y. Effects of positive inotropic agents on the relation between oxygen consumption and systolic pressure-volume area in canine left ventricle. Circ Res 1983a, 53: 306-318.

Suga H, Hisano R, Hirata S, Hayashi Y, Yamada O, Ninomiya I. Heart rate independent energetics and systolic pressure-volume area in dog heart. Am J Physiol Heart Circ Physiol 1983b, 244: H206-H214.

Suga H, Goto Y, Yamada O, Igarashi Y. Independence of myocardial oxygen consumption from pressure-volume trajectory during diastole in canine left ventricle. Circ Res 1984a, 55: 734-739.

Suga H, Yamada O, Goto Y, Igarashi Y, Ishiguri H. Constant mechanical efficiency of contractile machinery of canine left ventricle under different loading and inotropic conditions. Jpn J Physiol 1984b, 34: 679-689.

Suga H, Igarashi Y, Yamada O, Goto Y. Mechanical efficiency of the left ventricle as a function of preload, afterload, and contractility. Heart Vessel 1985, 1: 3-8.

Suga H, Yamada O, Goto Y, Igarashi Y. Peak isovolumic pressure-volume relation of puppy left ventricle. Am J Physiol Heart Circ Physiol 1986, 250: H167-H172.

Sultana C, Shen Y, Rattan V, Kalra VK. Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation. J Cell Physiol 1996; 167: 477-87.

Sunagawa K, Maughan WL, Sagawa K, et al. Effect of regional ischemia on the left ventricular end-systolic pressure–volume relationship of isolated canine hearts. Circ Res 1983;52:170.

Sunagawa K, Sagawa K, Maughan WL. Ventricular interaction with the loading system. Ann Biomed Eng 1984, 12: 163-189.

Svensson J, Hamberg M, Samuelsson B. On the formation and effects of thromboxane A 2 in human platelets. Acta Physiol Scand 1976; 98: 285-94.

Swanson ML, Lei ZM, Swanson PH, Rao CV, Narumiya S, Hirata M. The expression of thromboxane A 2 synthase and thromboxane A2 receptor gene in human uterus. Biol Reprod 1992; 47: 105-17.

Tada M,Kuzuya T, Hoshida S, Nishida M. Arachidonate metabolism in myocardial ischemia and reperfusion. J Mol Cell Cardiol 1988; 20(Suppl.2):135-43.

Taketo MM. COX-2 and colon cancer. Inflamm Res 1998; 47 Suppl 2: S112-6.

Takeuchi M, Odake M, Takaoka H, Hayashi Y, Yokoyama M. Comparison between preload recruitable stroke work and the end-systolic pressure-volume relationship in man. Eur Heart J 1992, 13 (supplement E): 80-84.

Tanabe M, Terashita ZI, Fujiwara S, et al. Coronary circulatory failure and thromboxane A 2 release during coronary occlusion and reperfusion in anaesthetised dogs. Cardiovasc Res 1982; 16:99-106.

Tazawa R, Green ED, Ohashi K, Wu KK, Wang LH. Characterization of the complete genomic structure of human thromboxane synthase gene and functional analysis of its promoter. Arch Biochem Biophys 1996; 334: 349-56.

Terao S, Shiraishi M, Matsumoto T, Ashida Y. [Thromboxane A 2 antagonist--discovery of seratrodast]. Yakugaku Zasshi 1999; 119: 377-90.

Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990; 85: 929.

Tesfamariam B, Brown ML, Cohen RA. 15-Hydroxyeicosatetraenoic acid and diabetic endothelial dysfunction in rabbit aorta. J Cardiovasc Pharmacol 1995; 25: 748-55.

Thomas DW, Mannon RB, Mannon PJ, et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A 2. J Clin Invest 1998; 102: 1994-2001.

Toki Y, Hieda N, Okumura K, Hashimoto H, Ito T, Ogawa K, and Satake T. Myocardial salvage by a novel thromboxane A 2 synthase inhibitor in a canine coronary occlusion-reperfusion model. Arzneim Forsch 1988; 38:224–227.

Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins & Other Lipid Mediators 2002; 68-9: 535-556.

Turek JW, Halmos T, Sullivan NL, Antonakis K, Le Breton GC. Mapping of a ligand-binding site for the human thromboxane A 2 receptor protein. J Biol Chem 2002; 277: 16791-7.

Tyson G, Maier G, Olsen C, Davis J, Rankin J. Pericardial influences on ventricular filling in the conscious dog: an analysis based on pericardial pressure. Circ Res 1984, 54: 173-184.

Ullrich V, Zou MH, Bachschmid M. New physiological and pathophysiological aspects on the thromboxane A 2-prostacyclin regulatory system. Biochim Biophys Acta 2001; 1532: 1-14.

Urakami A, Todo S, Zhu Y, et al. Attenuation of ischemic liver injury by monoclonal anti- endothelin antibody, AwETN40. J. Am. Coll. Surg 1997; 185: 358.

Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O , et al. Thromboxane A 2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med 1993; 178: 1825-30.

Utsonomiya T, Krausz MM, Levine L, Shepro D, Hechtman HB. Thromboxane mediation of cardiopulmonary effects of embolism. J Clin Invest 1982; 70: 361-8.

Van Diest MJ, Herman AG, Verbeuren TJ. Influence of hypercholesterolaemia on the reactivity of isolated rabbit arteries to15-lipoxygenase metabolites of arachidonic acid: comparison with platelet-derived agents and vasodilators. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 135-45.

Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989; 80: 1-9.

Vanhoutte PM. Hypercholesterolemia, atherosclerosis and release of endothelium-derived relaxing factors by aggregating platelets. Eur Heart J 1991; 12 (suppl. E): E3-12.

Vanhoutte PM, Scott-Burden T, et al. The endothelium in the health and disease. Tex Heart Inst J 1994; 21: 62-7.

Vanhoutte PM, Boulanger CM, Mombouli JV. Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 1995 ; 76: E3-12

Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-549.

Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Drugs Ther 1992; 6: 29-33.

Wacker MJ, Tehrani RN, Smoot RL, et al. Thromboxane A 2 mimetic evokes a bradycardia mediated by stimulation of cardiac vagal afferent nerves. Am J Physiol Heart Circ Physiol 2002; 282: H482-90.

Wacker MJ, Best SR, Kosloski LM, Stachura CJ, Smoot RL, Porter CB, Orr JA. Thromboxane

A2 –induced arrhythmias in the anesthetized rabbit. Am J Physiol Heart Circ Physiol 2006, 290: H1353-1361.

Walinsky P, Smith JB, Lefer AM, et al. Thromboxane A 2 in acute myocardial infarction. Am Heart J 1984; 108: 868-72.

Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 1995; 29:805.

Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004; 31: 64-73.

Walsh MT, Foley JF, Kinsella BT. The alpha, but not the beta, isoform of the human thromboxane A 2 receptor is a target for prostacyclin-mediated desensitization. J Biol Chem 2000; 275: 20412-23.

Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 223-32.

Warltier DC, Zyvoloski MG, Gross GJ, Hardman HF, and Brooks HL. Determination of experimental myocardial infarct size. J Pharmacol Methods 1981; 6:199–210.

Welch WJ and Wilcox CS. Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic. Role of macula densa. J Clin Invest 1992; 89: 1857-65.

Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997; 17: 3S-12S.

Wilcox CS, Welch WJ and Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int 1991; 40: 1090-7.

Wise H, Wong YH, Jones RL. Prostanoid signal integration and cross talk. Neurosignals 2002; 11: 20-8.

Wise WC, Cook JA, Halushka PV. Implications for thromboxane A2 in the pathogenesis of endotoxic shock. Adv Shock Res 1981; 6: 83-91.

Wong DR, Wang MA, Cheng Y, FitzGerald GA. Cardiovascular hazard and non-steroidal anti- inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204-10.

Wright DH, Abran D, Bhattacharya M, et al: Prostanoid receptors: ontogeny and implications in vascular physiology. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1343– R 1360.

Xiao CY, Hara A, Yuhki K, et al. Roles of prostaglandin I 2 and thromboxane A 2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 2001; 104:2210.

Yamamoto Y, Kamiya K, Terao S. Modeling of human thromboxane A 2 receptor and analysis of the receptor-ligand interaction. J Med Chem 1993; 36: 820-5.

Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.

Yang D, Zhang JN, Vanhoutte PM, Feletou M. NO and inactivation of the endothelium- dependent contracting factor released by acetylcholine in SHR. J Cardiovasc Pharmacol 2004; 43: 815-820.

Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ , et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001; 7: 2669-74.

Zamboni WA, Roth AC, Russell RC, Graham B, Suchy H, Kucan JO. Morphologic analysis of the microcirculation during reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen. Plast. Reconstr. Surg 1993 ; 91: 1110.

Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328:680.

.